Canadian Cancer Trials Group Bulletins


Recent Publication

The final results of Canadian Cancer Trials Group MA.27 - A Randomized Phase III Trial of Exemestane versus Anastrozole in Postmenopausal Women with Receptor Positive Primary Breast Cancer - were recently published online ahead of print on January 28, 2013.

This study, the first comparison of steroidal and nonsteroidal classes of aromatase inhibitors, showed neither exemestane nor anastrozole to be superior in terms of breast cancer outcomes as 5-year initial adjuvant therapy for postmenopausal breast cancer by two-way test. Less toxicity on bone is compatible with one hypothesis behind MA.27, but requires confirmation. Exemestane should be considered another option as up-front adjuvant therapy for postmenopausal hormone receptor-positive breast cancer.

To view the article, please use this link ...

An accompanying article has also been published online and is available here ...